ATOMOXETINE Drug Patent Profile
✉ Email this page to a colleague
When do Atomoxetine patents expire, and what generic alternatives are available?
Atomoxetine is a drug marketed by Apotex, Aurobindo Pharma, Dr Reddys, Glenmark Pharms Ltd, Hetero Labs Ltd V, Strides Pharma, Teva Pharms Usa, and Zydus Pharms Usa Inc. and is included in eight NDAs.
The generic ingredient in ATOMOXETINE is atomoxetine hydrochloride. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atomoxetine
A generic version of ATOMOXETINE was approved as atomoxetine hydrochloride by ZYDUS PHARMS USA INC on September 16th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ATOMOXETINE?
- What are the global sales for ATOMOXETINE?
- What is Average Wholesale Price for ATOMOXETINE?
Summary for ATOMOXETINE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Drug Prices: | Drug price information for ATOMOXETINE |
| What excipients (inactive ingredients) are in ATOMOXETINE? | ATOMOXETINE excipients list |
| DailyMed Link: | ATOMOXETINE at DailyMed |
US Patents and Regulatory Information for ATOMOXETINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma | ATOMOXETINE HYDROCHLORIDE | atomoxetine hydrochloride | CAPSULE;ORAL | 079021-006 | Feb 18, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hetero Labs Ltd V | ATOMOXETINE HYDROCHLORIDE | atomoxetine hydrochloride | CAPSULE;ORAL | 202682-004 | Mar 11, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva Pharms Usa | ATOMOXETINE HYDROCHLORIDE | atomoxetine hydrochloride | CAPSULE;ORAL | 079022-007 | May 30, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
